HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time
- PMID: 8599114
- DOI: 10.1126/science.271.5255.1582
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time
Abstract
A new mathematical model was used to analyze a detailed set of human immunodeficiency virus-type 1 (HIV-1) viral load data collected from five infected individuals after the administration of a potent inhibitor of HIV-1 protease. Productively infected cells were estimated to have, on average, a life-span of 2.2 days (half-life t 1/2 = 1.6 days), and plasma virions were estimated to have a mean life-span of 0.3 days (t 1/2 = 0.24 days). The estimated average total HIV-1 production was 10.3 x 10(9) virions per day, which is substantially greater than previous minimum estimates. The results also suggest that the minimum duration of the HIV-1 life cycle in vivo is 1.2 days on average, and that the average HIV-1 generation time--defined as the time from release of a virion until it infects another cell and causes the release of a new generation of viral particles--is 2.6 days. These findings on viral dynamics provide not only a kinetic picture of HIV-1 pathogenesis, but also theoretical principles to guide the development of treatment strategies.
Similar articles
-
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.Nature. 1995 Jan 12;373(6510):123-6. doi: 10.1038/373123a0. Nature. 1995. PMID: 7816094
-
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.N Engl J Med. 1995 Dec 7;333(23):1534-9. doi: 10.1056/NEJM199512073332204. N Engl J Med. 1995. PMID: 7477168 Clinical Trial.
-
Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.J Infect Dis. 1996 Feb;173(2):321-9. doi: 10.1093/infdis/173.2.321. J Infect Dis. 1996. PMID: 8568292 Clinical Trial.
-
HIV-1 dynamics in vivo: implications for therapy.Nat Rev Microbiol. 2003 Dec;1(3):181-90. doi: 10.1038/nrmicro772. Nat Rev Microbiol. 2003. PMID: 15035022 Review.
-
Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.HIV Clin Trials. 2008 Nov-Dec;9(6):418-27. doi: 10.1310/hct0906-418. HIV Clin Trials. 2008. PMID: 19203907 Review.
Cited by
-
Hepatitis C viral kinetics: the past, present, and future.Clin Liver Dis. 2013 Feb;17(1):13-26. doi: 10.1016/j.cld.2012.09.003. Clin Liver Dis. 2013. PMID: 23177280 Free PMC article. Review.
-
Promoter Targeting RNAs: Unexpected Contributors to the Control of HIV-1 Transcription.Mol Ther Nucleic Acids. 2015 Jan 27;4(1):e222. doi: 10.1038/mtna.2014.67. Mol Ther Nucleic Acids. 2015. PMID: 25625613 Free PMC article. Review.
-
T cell independent secondary antibody responses to the envelope protein of simian immunodeficiency virus.Retrovirology. 2012 May 14;9:42. doi: 10.1186/1742-4690-9-42. Retrovirology. 2012. PMID: 22583867 Free PMC article.
-
Stability of an HTLV-HIV coinfection model with multiple delays and CTL-mediated immunity.Adv Differ Equ. 2021;2021(1):270. doi: 10.1186/s13662-021-03416-7. Epub 2021 May 25. Adv Differ Equ. 2021. PMID: 34054935 Free PMC article.
-
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.Angew Chem Int Ed Engl. 2012 Feb 20;51(8):1778-802. doi: 10.1002/anie.201102762. Epub 2012 Jan 31. Angew Chem Int Ed Engl. 2012. PMID: 22290878 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical